To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
Condition: COVID-19 Intervention: Biological: Recombinant Novel Coronavirus vaccine (CHO Cells) Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials